Neogen (NASDAQ:NEOG) Stock Price Down 5.5% – Should You Sell?

Shares of Neogen Corporation (NASDAQ:NEOG) were down 5.5% during trading on Friday . The company traded as low as $8.44 and last traded at $9.1790. Approximately 1,803,973 shares traded hands during trading, a decline of 71% from the average daily volume of 6,287,906 shares. The stock had previously closed at $9.71.

More Neogen News

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Q2 results beat consensus on key metrics and management raised FY2026 revenue guidance to $845–$855M (above consensus), signaling progress on a turnaround; investors liked the combination of revenue outperformance and guidance lift. Neogen Raises Guidance as Cost-Cutting Takes Hold
• Positive Sentiment: Market reaction: the stock spiked sharply (reports note moves >30%) after the earnings and guidance, reflecting renewed investor optimism about revenue growth and cost actions. Why Neogen Stock Blasted More Than 31% Higher Today
• Positive Sentiment: Heavy bullish options activity and call buying accompanied the move (unusually large call volume), suggesting speculative and institutional interest in the near-term upside. Neogen Posts Strong Q2 Earnings
• Neutral Sentiment: Analyst & institutional context: a small number of upgrades and divergent price targets mean consensus is still forming; some funds have been reallocating positions into/out of NEOG. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Underlying GAAP metrics remain mixed: some reports show the company recorded operating and net losses and weaker operating cash flow in the quarter (contrast between adjusted EPS and GAAP results creates ambiguity about sustainable profitability). That tempers the bullish narrative and raises execution risk. QuiverQuant Q2 Earnings Summary

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. CJS Securities raised Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, December 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Neogen in a research report on Monday, December 29th. Guggenheim reaffirmed a “buy” rating and set a $12.00 price objective (up from $8.00) on shares of Neogen in a research report on Friday. Wall Street Zen downgraded Neogen from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Piper Sandler set a $6.50 target price on shares of Neogen and gave the stock a “neutral” rating in a research note on Thursday, October 16th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.50.

Neogen Price Performance

The firm has a 50-day moving average of $6.66 and a 200-day moving average of $5.89. The stock has a market cap of $2.09 billion, a PE ratio of -3.47 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.91 and a quick ratio of 2.26.

Neogen (NASDAQ:NEOG) last posted its quarterly earnings results on Thursday, January 8th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.03. Neogen had a positive return on equity of 2.14% and a negative net margin of 68.47%.The business had revenue of $224.69 million during the quarter, compared to the consensus estimate of $208.50 million. During the same period in the prior year, the company posted $0.11 EPS. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. Research analysts predict that Neogen Corporation will post 0.38 EPS for the current year.

Institutional Trading of Neogen

Institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its holdings in shares of Neogen by 217.0% during the 1st quarter. AQR Capital Management LLC now owns 52,410 shares of the company’s stock valued at $443,000 after purchasing an additional 35,878 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Neogen by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 129,813 shares of the company’s stock worth $1,125,000 after buying an additional 5,638 shares in the last quarter. Millennium Management LLC bought a new position in Neogen during the first quarter valued at approximately $20,761,000. Jones Financial Companies Lllp boosted its stake in Neogen by 5,687.3% during the first quarter. Jones Financial Companies Lllp now owns 33,393 shares of the company’s stock valued at $290,000 after buying an additional 32,816 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Neogen by 14.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,678,493 shares of the company’s stock valued at $14,553,000 after buying an additional 209,990 shares in the last quarter. 96.73% of the stock is currently owned by institutional investors.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.